Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 3/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202449 | 0.80 | MDM2 (0.33) | — | |
| Bicarbonate SCHEMBL10976674 | 0.57 | KDM1A (0.54) | KDM1ARCOR1CCR6KCNH2 | |
| SCHEMBL28503275 | 0.56 | PDE5A (0.41) | KDM1ARCOR1CCR6KCNH2ALDH1A1 | |
| SCHEMBL18998470 | 0.55 | KDM1A (0.47) | KDM1ARCOR1CCR6KCNH2ALDH1A1 | |
| SCHEMBL18998726 | 0.55 | KDM1A (0.47) | KDM1ARCOR1CCR6KCNH2ALDH1A1 | |
| SCHEMBL12875677 | 0.55 | KDM1A (0.47) | KDM1ARCOR1CCR6KCNH2ALDH1A1 | |
| SCHEMBL28885355 | 0.54 | KDM1A (0.50) | KDM1ARCOR1 | |
| SCHEMBL25004310 | 0.54 | TSHR (0.56) | KDM1ARCOR1CCR6KCNH2ALDH1A1 | |
| SCHEMBL14438091 | 0.54 | HTR2A (0.53) | KDM1ARCOR1CCR6KCNH2ALDH1A1 | |
| SCHEMBL7880508 | 0.54 | L3MBTL1 (0.68) | KDM1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | KDM1A 3678/4885RCOR1 842/4885CCR6 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.